Page 38 - Noble-Virtual-Healthcare-2024

Health Care
Date April 15, 2024 Health Care
52wk High $4.53
52wk Low $1.95 Lisata Therapeutics, Inc. LSTA $2.87
110 Allen Road
Basking Ridge, NJ 07920

(USD - in millions) www.lisata.com
Market Cap 24.1
Enterprise (26.4)
Basic Shares Out. 8.31 COMPANY OVERVIEW
Float 6.75
Institutional Holdings 9.00% Detailed Analysis:Channelchek.com
Short Interest 0.02
Avg. 90-Day Volume 0.01 Lisata Therapeutics is a clinical-stage pharmaceutical company
dedicated to the discovery, development and commercialization of
innovative therapies for the treatment of advanced solid tumors and
other major diseases. Lisata’s lead product candidate, LSTA1, is an
EPS Data investigational drug designed to activate a novel uptake pathway that
allows co-administered or tethered anti-cancer drugs to target and
2021 2022 2023 penetrate solid tumors more effectively. Based on Lisata’s CendR
CQ1 (2.85) (1.05) (0.77) Platform® Technology, Lisata has already established noteworthy
CQ2 (1.50) (1.65) (0.50) commercial and R&D partnerships.

CQ3 (1.80) (1.47) (0.65)
CQ4 (1.65) (0.76) (0.66)
CY (7.50) (4.60) (2.58) Source: Channelchek/QuoteMedia

Long-Term EPS Estimate N/A
Price/Book (mrq) 5.91
ROE (ttm) -36.49
Debt-to-Total Cap. (mrq) 0.63
Fiscal Year End 31-Dec
110 Allen Roa Basking RidgeNJ 07920

Key Executives
CEO: Mazzo, David
CFO: Nisco, James
COO: Imam, Tariq
IR: Menditto, John
Noble Capital Markets, Inc.
Source: Capital IQ, Noble Financial estimates, company filings
Noble Senior Analyst 561-994-1191 noblecapitalmarkets.com
Robert Leboyer MEMBERS: FINRA, SIPC, MSRB
rleboyer@noblelsp.com Following the conference, complete video library of presentations will be
available at: channelchek.com | nobleconference.com
(212) 896-4625

Refer to the back of the book for disclosures